310 related articles for article (PubMed ID: 19382527)
1. Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them.
Baughman RP; Lower EE; Drent M
Sarcoidosis Vasc Diffuse Lung Dis; 2008 Dec; 25(2):76-89. PubMed ID: 19382527
[TBL] [Abstract][Full Text] [Related]
2. [TNFα blocking agents and sarcoidosis: an update].
Toussirot E; Pertuiset E
Rev Med Interne; 2010 Dec; 31(12):828-37. PubMed ID: 20510487
[TBL] [Abstract][Full Text] [Related]
3. Anti-TNF therapeutics for the treatment of sarcoidosis.
Crommelin HA; Vorselaars AD; van Moorsel CH; Korenromp IH; Deneer VH; Grutters JC
Immunotherapy; 2014; 6(10):1127-43. PubMed ID: 25428650
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab.
Crommelin HA; van der Burg LM; Vorselaars AD; Drent M; van Moorsel CH; Rijkers GT; Deneer VH; Grutters JC
Respir Med; 2016 Jun; 115():72-7. PubMed ID: 27215507
[TBL] [Abstract][Full Text] [Related]
5. Steroid-resistant sarcoidosis: is antagonism of TNF-alpha the answer?
Denys BG; Bogaerts Y; Coenegrachts KL; De Vriese AS
Clin Sci (Lond); 2007 Mar; 112(5):281-9. PubMed ID: 17261090
[TBL] [Abstract][Full Text] [Related]
6. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
Gniadecki R; Kragballe K; Dam TN; Skov L
Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
[TBL] [Abstract][Full Text] [Related]
7. Refractory chronic cutaneous sarcoidosis responsive to dose escalation of TNF-alpha antagonists.
Thielen AM; Barde C; Saurat JH; Laffitte E
Dermatology; 2009; 219(1):59-62. PubMed ID: 19468200
[TBL] [Abstract][Full Text] [Related]
8. Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients.
Riancho-Zarrabeitia L; Calvo-Río V; Blanco R; Mesquida M; Adan AM; Herreras JM; Aparicio Á; Peiteado-Lopez D; Cordero-Coma M; García Serrano JL; Ortego-Centeno N; Maíz O; Blanco A; Sánchez-Bursón J; González-Suárez S; Fonollosa A; Santos-Gómez M; González-Vela C; Loricera J; Pina T; González-Gay MA
Semin Arthritis Rheum; 2015 Dec; 45(3):361-8. PubMed ID: 26092330
[TBL] [Abstract][Full Text] [Related]
9. Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect.
Iborra M; Beltrán B; Bastida G; Aguas M; Nos P
J Crohns Colitis; 2011 Apr; 5(2):157-61. PubMed ID: 21453886
[TBL] [Abstract][Full Text] [Related]
10. TNF-α: a treatment target or cause of sarcoidosis?
Amber KT; Bloom R; Mrowietz U; Hertl M
J Eur Acad Dermatol Venereol; 2015 Nov; 29(11):2104-11. PubMed ID: 26419478
[TBL] [Abstract][Full Text] [Related]
11. [Nasosinusal and cervical sarcoidosis: a case series of three patients and literature review].
Hermet M; le Guenno G; Rieu V; Philippe P; Ruivard M
Rev Med Interne; 2012 Jan; 33(1):46-9. PubMed ID: 21601318
[TBL] [Abstract][Full Text] [Related]
12. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
[TBL] [Abstract][Full Text] [Related]
13. [Autoimmune aspects of treatment with TNF-alpha inhibitors].
Kolarz B; Targońska-Stepniak B; Darmochwał-Kolarz D; Majdan M
Postepy Hig Med Dosw (Online); 2007 Aug; 61():478-84. PubMed ID: 17786135
[TBL] [Abstract][Full Text] [Related]
14. Patient outcomes after anti TNF-alpha drugs for Crohn's disease.
Assasi N; Blackhouse G; Xie F; Marshall JK; Irvine EJ; Gaebel K; Robertson D; Campbell K; Hopkins R; Goeree R
Expert Rev Pharmacoecon Outcomes Res; 2010 Apr; 10(2):163-75. PubMed ID: 20384563
[TBL] [Abstract][Full Text] [Related]
15. Tumour necrosis factor in sarcoidosis and its potential for targeted therapy.
Baughman RP; Iannuzzi M
BioDrugs; 2003; 17(6):425-31. PubMed ID: 14614765
[TBL] [Abstract][Full Text] [Related]
16. Anti-TNF agents in familial Mediterranean fever: report of three cases and review of the literature.
Ozgocmen S; Akgul O
Mod Rheumatol; 2011 Dec; 21(6):684-90. PubMed ID: 21567247
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy of adalimumab in paediatric Crohn's disease patients naïve to other anti-TNF therapies.
Martín-de-Carpi J; Pociello N; Varea V
J Crohns Colitis; 2010 Nov; 4(5):594-8. PubMed ID: 21122566
[TBL] [Abstract][Full Text] [Related]
18. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.
Finckh A; Simard JF; Gabay C; Guerne PA;
Ann Rheum Dis; 2006 Jun; 65(6):746-52. PubMed ID: 16339288
[TBL] [Abstract][Full Text] [Related]
19. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study.
Lim LL; Fraunfelder FW; Rosenbaum JT
Arthritis Rheum; 2007 Oct; 56(10):3248-52. PubMed ID: 17907169
[TBL] [Abstract][Full Text] [Related]
20. Anti-TNF agents for the treatment of psoriasis.
Kircik LH; Del Rosso JQ
J Drugs Dermatol; 2009 Jun; 8(6):546-59. PubMed ID: 19537380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
